Mines Management Inc.
http://www.minesmanagement.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mines Management Inc.
Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
InDex's Lead TLR9 Agonist Shows Promise In Ulcerative Colitis
A Toll-like receptor-9 agonist under development by Sweden’s InDex Pharmaceuticals showed encouraging clinical responses in top-line results in patients with active ulcerative colitis not responding to other agents. Its novel mechanism of action and relatively benign side effect profile makes it a prime candidate to combine with biologic agents.
Mologen To Pursue Combinations Only After Lefitolimod’s Solo IMPALA Failure
Mologen’s CEO tells Scrip the German biotech will only pursue combination studies in future after its lead candidate lefitolimod failed as a monotherapy in a pivotal trial treating metastatic colorectal cancer patients.
Key Catalyst In August For Mologen As IMPALA Phase III Colorectal Cancer Reports
Mologen CEO says next month’s pivotal trial topline readout on its lead asset lefitolimod will be important for the German-based immunotherapy pioneer of DNA-based TLR9 agonists.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Minera Montanore Peru SAC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice